Hypothesis

Combining oral Urolithin A (UA) supplementation with a defined probiotic cocktail that enriches Gordonibacter, Ellagibacter and Bifidobacterium spp. will not only raise circulating UA levels but also suppress gut‑microbial production of phenylacetic acid (PAA). Lower PAA will diminish endothelial cell senescence, thereby decreasing inflammaging and allowing UA‑induced mitophagy in skeletal muscle to operate more efficiently. This dual action should produce additive improvements in mitochondrial health markers beyond those seen with UA alone.

Mechanistic Rationale

UA is a potent mitophagy activator that improves mitochondrial gene expression and acylcarnitine profiles in older adults [1]. Its efficacy, however, is limited to individuals harboring the requisite UA‑producing microbiota (metabotype UM-A) [2]. In contrast, age‑related dysbiosis elevates circulating PAA, which directly drives endothelial senescence via oxidative stress and DNA damage signaling [3]. Mitochondrial dysfunction fuels senescence through ROS burst and aberrant mTOR activation [4][5], creating a feed‑forward loop that worsens inflammaging.

We propose that UA, beyond its role as a mitophagy inducer, acts as a signaling molecule in the gut epithelium. Structural similarity to benzoic acid derivatives enables UA to bind the transcriptional regulator HNF4α, upregulating host phenylalanine hydroxylase (PAH) and downregulating bacterial phenylacetate‑CoA ligase activity. This shifts phenylalanine metabolism away from the PAA pathway toward tyrosine and downstream catecholamines, reducing luminal PAA production. Supporting this, UA’s anti‑inflammatory potency—shown by inhibition of myeloperoxidase and lactoperoxidase [6]—suggests it can modulate microbial enzyme expression through host‑mediated redox shifts.

When UA‑producing probiotics are co‑administered, they increase UA synthesis while the UA‑mediated transcriptional reprogramming curtails PAA outflow. The resulting decline in circulating PAA lessens endothelial senescence, lowering SASP cytokines (IL‑6, IL‑1β, TNF‑α) that otherwise exacerbate mitochondrial dysfunction and inhibit mitophagy. Consequently, UA‑driven PINK1/Parkin activation and mitochondrial fission/fusion remodeling proceed with less inhibitory signaling, yielding greater increases in mtDNA copy number, citrate synthase activity, and improved PGC‑1α expression.

Testable Predictions

1. Metabolite shift – In older adults classified as UM‑B (non‑producers), a 12‑week regimen of UA (500 mg day⁻¹) + probiotic blend will reduce fasting plasma PAA by ≥20 % relative to UA‑alone and placebo groups (measured by LC‑MS/MS).
2. Endothelial senescence – Circulating senescence markers (p16^INK4a^‑positive extracellular vesicles, plasma SASP) will decrease significantly only in the combination arm.
3. Mitophagy amplification – Skeletal‑muscle biopsies will show a larger increase in LC3‑II/I ratio, PINK1 phosphorylation, and Parkin translocation in the combination group versus UA‑alone (≥30 % greater change).
4. Mitochondrial health – Improvements in acylcarnitine profile, mitochondrial gene expression (NDUFS4, COX4I1) and functional assays (ATP production, ROS emission) will be additive, exceeding the sum of effects observed with each monotherapy.

Falsifiability

If the combination fails to lower plasma PAA or does not produce a statistically significant additive benefit on any of the above endpoints compared with UA alone, the hypothesis is refuted. Conversely, a confirmed PAA reduction coupled with enhanced mitophagy and mitochondrial outcomes would substantiate the proposed gut‑metabolite‑mitochondria crosstalk.

References

[1] https://www.autophagy.center/metabolism/mitophagy-activator-urolithin-safe-and-induces-molecular-signature-improved [2] https://pubs.acs.org/doi/10.1021/acs.jafc.2c08889 [3] https://doi.org/10.1101/2023.11.17.567594 [4] https://doi.org/10.1111/acel.12287 [5] https://doi.org/10.1016/j.exger.2014.11.004 [6] https://pmc.ncbi.nlm.nih.gov/articles/PMC4890745/